US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States

Saran, Rajiv; Robinson, Bruce M.; Abbott, Kevin C.; Bragg‐Gresham, Jennifer L.; Chen, Xiaoying; Gipson, Debbie S.; Gu, Haoyu; Hirth, Richard A.; Hutton, David; Jin, Yan; Kapke, Alissa; Kurtz, Vivian; Li, Yiting; McCullough, Keith; Modi, Zubin; Morgenstern, Hal; Mukhopadhyay, Purna; Pearson, Jeffrey; Pisoni, Ronald L.; Repeck, Kaitlyn; Schaubel, Douglas E.; Shamraj, Ruth; Steffick, Diane; Turf, Megan; Woodside, Kenneth J.; Xiang, Jie; Yin, Maggie; Zhang, Xiaosong; Shahinian, Vahakn B.

doi:10.1053/j.ajkd.2019.09.003

Cited by 633 publications

(483 citation statements)

References 0 publications

Supporting

Mentioning

461

Contrasting

Unclassified

Order By: Relevance

“…The arteriovenous fistula (AVF) is the preferred vascular access for chronic hemodialysis [1]. It is surgically created by directly connecting a vein to an artery, usually in the upper extremity, and requires the venous lumen to become sufficiently large (maturation) for successful cannulation.…”

Section: Introductionmentioning

confidence: 99%

“…It is surgically created by directly connecting a vein to an artery, usually in the upper extremity, and requires the venous lumen to become sufficiently large (maturation) for successful cannulation. AVF maturation failure is a significant clinical problem in the hemodialysis population [1]. Many factors contribute to AVF maturation failure, and the exact pathophysiologic mechanisms are not completely understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Geometry of Arteriovenous Fistulas Using Endothelial Nitric Oxide Synthase Mouse Models

et al. 2020

View full text Add to dashboard Cite

BackgroundArteriovenous fistula (AVF) maturation failure is a significant clinical problem in the hemodialysis population. Geometric parameters of human AVFs were associated with AVF development, but causative studies are lacking. We characterized mouse AVF geometry using endothelial nitric oxide synthase (NOS3) mouse models.MethodsCarotid-jugular AVFs were created in NOS3 overexpression (OE), knockout (KO), and wild-type (WT) mice. At 7 and 21 days postcreation, black-blood magnetic resonance images of AVFs were acquired and used to build three-dimensional reconstructions of AVF lumens. We used these reconstructions to calculate the lumen area, lumen centerline, and centerline-derived parameters: anastomosis angle, tortuosity, nonplanarity angle, and location of maximal distance between the feeding artery and AVF vein. Inter- and intrauser variabilities were also determined.ResultsWhen all mice were considered, increased minimum AVF venous lumen area was accompanied by increased venous tortuosity and increased distance between the artery and vein, with both remaining in plane with the anastomosis. At day 7, the lumen area of AVFs from all strains was 1.5- to 2.5-fold larger than native veins. Furthermore, at day 21, AVF lumen in NOS3 OE (4.04±1.43 mm2) was significantly larger than KO (2.74±1.34 mm2) (P<0.001) and WT (2.94±1.30 mm2) mice (P<0.001). At day 21, the location of maximal artery-vein distance on the vein was further away from the anastomosis in OE (4.49±0.66 mm) than KO (2.87±0.38 mm) (P=0.01). Other geometric parameters were not significantly different between mouse strains or time points. Inter- and intrauser variabilities were small, indicating the reliability and reproducibility of our protocol.ConclusionsOur study presents a detailed characterization of mouse AVF geometry, and a robust protocol for future mechanistic studies to investigate the role of molecular pathways in AVF geometry. Identifying a geometry related to desired AVF remodeling can help inform surgery to enhance AVF maturation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Geometry of Arteriovenous Fistulas Using Endothelial Nitric Oxide Synthase Mouse Models

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is well known that chronic kidney disease (CKD) confers a markedly increased cardiovascular risk, especially when it progresses to end-stage renal disease (ESRD) [1,2]. Among the nontraditional and uremia-related risk factors accounting for such prominent cardiovascular burden, hyperhomocysteinemia (HHcy) is commonly found in CKD patients because of impaired renal metabolism and excretion [3].…”

Section: Introductionmentioning

confidence: 99%

Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery

Cappuccilli

Bergamini²,

Giacomelli³

et al. 2020

Nutrients

View full text Add to dashboard Cite

Cardiovascular morbidity and mortality are several-fold higher in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) than in the general population. Hyperhomocysteinemia has undoubtedly a central role in such a prominent cardiovascular burden. The levels of homocysteine are regulated by methyl donors (folate, methionine, choline, betaine), and cofactors (vitamin B6, vitamin B12,). Uremia-induced hyperhomocysteinemia has as its main targets DNA methyltransferases, and this leads to an altered epigenetic control of genes regulated through methylation. In renal patients, the epigenetic landscape is strictly correlated with the uremic phenotype and dependent on dietary intake of micronutrients, inflammation, gut microbiome, inflammatory status, oxidative stress, and lifestyle habits. All these factors are key contributors in methylome maintenance and in the modulation of gene transcription through DNA hypo- or hypermethylation in CKD. This is an overview of the epigenetic changes related to DNA methylation in patients with advanced CKD and ESRD. We explored the currently available data on the molecular dysregulations resulting from altered gene expression in uremia. Special attention was paid to the efficacy of B-vitamins supplementation and dietary intake of methyl donors on homocysteine lowering and cardiovascular protection.

show abstract

“…[1] Type 2 DM is the leading cause of chronic kidney disease (CKD); it accounts for about 36 % of adult CKD in the United States. [2] CKD with DM can progress to end-stage renal disease (ESRD), [3] which confers a poor overall prognosis. Moreover, type 2 DM and CKD increase the risk of cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis

Yamada¹,

Bhalla²,

Wakabayashi³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundBoth sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date has compared the effect of SGLT-2 inhibitors with that of GLP-1 RAs in type 2 DM patients with chronic kidney disease (CKD). We herein investigated the benefits of SGLT-2 inhibitors and GLP-1 RAs in CKD patients.MethodsWe performed a systematic literature search through July 2020. We selected randomized control trials that compared the risk of major adverse cardiovascular events (MACE) and a composite of renal outcomes. We performed a network meta-analysis to compare SGLT-2 inhibitors with GLP-1 RA indirectly. Risk ratios (RRs) with corresponding 95 % confidence interval (CI) were synthesized.ResultsFifteen studies were selected with a total of 20,947 patients. SGLT-2 inhibitors led to a risk reduction in MACE (RR [95 % CI]; 0.80 [0.70-0.91]) , but GLP-1 RAs did not (RR 0.89 [0.78-1.00]). Compared to GLP-1 RAs, SGLT-2 inhibitors did not demonstrate a significant difference (RR 0.90 [0.75-1.08]). Similarly, SGLT-2 inhibitors significantly decreased renal events (RR 0.66 [0.58-0.75]), but GLP-1 RAs did not (RR 0.80 [0.90-1.00]). SGLT-2 inhibitors were also associated with a lower risk of renal events compared to GLP-1 RAs (RR 0.73 [0.62-0.87]).ConclusionsIn patients with type 2 DM and CKD, SGLT-2 inhibitors were associated with a decreased risk of cardiovascular and renal events, but GLP-1 RA were not. SGLT-2 inhibitors significantly decreased the risk of renal events compared to GLP-1 RAs.

show abstract

US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States

Cited by 633 publications

References 0 publications

The Geometry of Arteriovenous Fistulas Using Endothelial Nitric Oxide Synthase Mouse Models

The Geometry of Arteriovenous Fistulas Using Endothelial Nitric Oxide Synthase Mouse Models

Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery

Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis

Contact Info

Product

Resources

About